Tech Company Financing Transactions
VelosBio Funding Round
VelosBio, based in San Diego, scored $137 million from Matrix Capital Management, Surveyor Capital and Adage Capital Management.
Transaction Overview
Company Name
Announced On
7/9/2020
Transaction Type
Venture Equity
Amount
$137,000,000
Round
Series B
Investors
Matrix Capital Management (Lead Investor)
Surveyor Capital (Lead Investor)
Proceeds Purpose
The company intends to use the funds to further advance the clinical development of the VelosBio lead antibody-drug conjugate (ADC), VLS-101, and support the continued expansion of its pipeline of ROR1-directed next-generation ADCs and bispecific antibodies.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
11045 Roselle St. 130
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
VelosBio is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Johnson
Chief Medical Officer
Langdon Miller
President
Clayton Knox
Vice President
Jeffry Watkins
VP - Manufacturing
Michael Sun
Browse more venture capital transactions:
Prev: 7/9/2020: Karma Automotive venture capital transaction
Next: 7/9/2020: SMARTcare Software venture capital transaction
Share this article
News on VC Transactions
We do our best to document every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs